Ambry launches StemArray for characterising human stem cells
This article was originally published in Clinica
Ambry Genetics has launched its StemArray product and services for detecting abnormalities in human stem cells. The test uses array comparative genomic hybridisation (aCGH) technology to cover the entire genome, detecting defects that are missed by conventional low-resolution karyotyping, the Aliso Viejo, California firm claims. StemArray is designed for use with human embryonic and induced pluripotent stem cells, which are susceptible to chromosomal instability when cultured for long periods of time. These abnormalities can decrease the reproducibility and reliability of experimental data. Ambry is offering the product at a comparable cost to traditional karyotyping, it said.